Tag Archive for: Alzheimer’s

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

Significant appointments of industry and academic experts to support Phase II development of ASN51 in Alzheimer’s disease Lausanne, SWITZERLAND and San Francisco, CA, USA, 6 March 2024 – Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board […]

AstronauTx closes £48 million ($61 million) Series A financing to create new treatments for Alzheimer’s disease

AstronauTx is a biotech company developing new treatments for neurodegenerative conditions based on amplifying the brain’s own physiological protective mechanisms Proceeds of the financing will be used to advance a portfolio of programmes and take the lead molecule into clinical trials The syndicate, led by the Novartis Venture Fund, also includes MPM Capital, Brandon Capital, […]

Asceneuron Publishes Pioneering Preclinical Efficacy Data on its Novel Clinical Molecule ASN90 in Both Alzheimer’s and Parkinson’s Disease Models

Findings published in the peer-reviewed journal ACS Chemical Neuroscience demonstrated increased survival in preclinical model of Alzheimer’s disease after administration of clinical molecule ASN90, as well as significant motor impairment and astrogliosis effect in a Parkinson’s model Unique functional benefits in gold-standard preclinical models of Alzheimer’s and Parkinson’s disease highlight the significant potential of O-GlcNAcase […]

IXICO to Present Abstracts at Upcoming Clinical Trials on Alzheimer’s Disease Congress

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience clinical drug development, today announces that it is scheduled to attend and present scientific posters at the 2019 Clinical Trials on Alzheimer’s Disease (CTAD) Congress held from 4th-7th December 2019 in San Diego, California, USA. CTAD Congress 2019 4th – 7th December […]